查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1820342

2025 年至 2033 年免疫球蛋白市场规模、份额、趋势及预测（按产品、应用、交付方式及地区划分）

Immunoglobulin Market Size, Share, Trends and Forecast by Product, Application, Mode of Delivery, and Region, 2025-2033
出版日期: | 出版商: IMARC | 英文 150 Pages | 商品交期: 2-3个工作天内

价格

2024年，全球免疫球蛋白市场规模为164.5亿美元。展望未来， IMARC Group估计，到2033年，市场规模将达到257.7亿美元，2025-2033年期间的复合年增长率为4.70%。目前，北美占据市场主导地位，到2024年将占46.5%的份额。市场发展的主要驱动因素包括：免疫疾病发病率上升、老年人口增加、免疫疗法治疗的持续进步、神经病学和血液学领域产品应用的不断扩大，以及人们对原发性免疫缺陷病 (PIDD) 和其他自体免疫疾病的认识不断提高。

市场的主要驱动因素是免疫缺陷疾病（例如原发性和继发性免疫缺陷）的盛行率上升，从而增加了对免疫球蛋白疗法的需求。此外，正在进行的临床研究以及免疫球蛋白製剂（例如皮下和静脉给药方法）的创新正在推动市场成长。例如，2024 年 10 月 22 日，大冢製药发布了其关于西吡崙单抗治疗成人 IgAN 患者的 III 期 VISIONARY 研究的有希望的中期结果。该研究在九个月后达到了主要终点，与安慰剂相比，24 小时 uPCR 临床显着下降，且不影响安全性。此外，对自体免疫疾病的认识和诊断不断提高，增加了免疫球蛋白作为一种有效治疗方式的使用。

由于重症肌无力和多灶性运动神经病变等罕见神经系统疾病的发生率不断上升，美国市场正在经历显着增长，这刺激了对免疫球蛋白疗法的需求。此外，美国拥有先进的医疗基础设施，使得人们更容易获得高成本的治疗，这使得美国成为免疫球蛋白产品的重要市场。此外，美国实施的优惠政策和已获批准的认证进一步扩大了免疫球蛋白治疗的可及性，确保了该领域的持续市场成长和创新。 2024年6月17日，基立福（Grifols）宣布其子公司Biotest已获得美国FDA批准用于治疗原发性免疫缺陷的静脉注射免疫球蛋白Yimmugo。这标誌着Biotest首个获得FDA批准的治疗药物在其位于德国德赖艾希的全新「Next Level」工厂生产。 Yimmugo(R) 将于 2024 年下半年在美国上市，预计将为 Grifols Group 的销售额做出重大贡献，并支持其未来的成长策略。

免疫球蛋白市场趋势：

免疫疾病盛行率不断上升

免疫疾病（例如骨盆腔发炎性脱髓鞘多发性神经病变 (PIDD)、慢性发炎性脱髓鞘多发性神经病变 (CIDP) 和川崎病）的发生率不断上升，是推动免疫球蛋白市场发展的关键趋势之一。例如，每年每 10 万人中约有 1-2 例 CIDP 新病例。这些疾病会削弱人体免疫系统，使其更容易受到感染。随着越来越多的患者被诊断出患有免疫相关疾病，对免疫球蛋白疗法的需求也随之增长。骨盆腔发炎性脱髓鞘多发性神经病变 (PIDD) 包含 300 多种不同的罕见疾病，在已开发经济体和新兴经济体中都越来越受到关注。早期诊断和治疗对于控制这些疾病至关重要，这进一步增加了作为主要治疗方案的免疫球蛋白的需求。

血浆衍生疗法的进展

血浆衍生疗法的持续进步是推动市场成长的重要因素。免疫球蛋白主要来自人体血浆。血浆采集和纯化的技术进步进一步提高了生产效率。这些创新有助于提高免疫球蛋白产品的可靠供应。此外，製造工艺的创新也提高了这些疗法的品质、安全性和有效性。 SCIG产品的开发允许患者在家中自行给药，方便了患者并提高了治疗依从性。此外，不依赖血浆捐赠的重组免疫球蛋白产品的出现，有可能缓解供应紧张，并提供替代治疗方案，从而支持免疫球蛋白市场的成长。

拓展各医疗领域的应用

免疫球蛋白疗法在各个医疗领域的应用日益广泛，这为市场成长提供了动力。除了传统的免疫学用途外，免疫球蛋白也广泛应用于神经病学、血液学甚至肿瘤学。例如，美国在2023年用于肿瘤学的支出为990亿美元，高于2019年的650亿美元。例如，在神经病学领域，免疫球蛋白疗法越来越多地用于治疗格林-巴利综合症、多发性硬化症和重症肌无力等疾病。在血液学领域，免疫球蛋白用于治疗自体免疫溶血性贫血和特发性血小板减少性紫斑症(ITP)。这些不断扩展的应用得到了正在进行的临床试验和研究工作的支持，这些试验和研究旨在探索免疫球蛋白在更广泛疾病中的应用，从而对免疫球蛋白市场前景产生积极影响。

目录

第一章：前言

第二章：范围与方法

  • 研究目标
  • 利害关係人
  • 资料来源
    • 主要来源
    • 二手资料
  • 市场评估
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第三章：执行摘要

第四章：简介

第五章：全球免疫球蛋白市场

  • 市场概况
  • 市场表现
  • COVID-19的影响
  • 市场预测

第六章：市场区隔：依产品

  • 免疫球蛋白G
  • 免疫球蛋白A
  • 免疫球蛋白M
  • 免疫球蛋白E
  • 免疫球蛋白D

第七章：市场区隔：依应用

  • 低丙种球蛋白血症
  • 慢性发炎性脱髓鞘多发性神经病变（CIDP）
  • 免疫缺陷症
  • 重症肌无力
  • 其他的

第八章：市场区隔：依交付方式

  • 静脉给药方式
  • 皮下给药方式

第九章：市场细分：依地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲

第 10 章：SWOT 分析

第 11 章：价值链分析

第 12 章：波特五力分析

第十三章：价格分析

第 14 章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • ADMA Biologics Inc.
    • Baxter international Inc.
    • Biotest AG
    • CSL Limited
    • Grifols SA
    • Kedrion SpA
    • LFB SA
    • Octapharma AG
    • Sanquin Plasma Products BV
    • Takeda Pharmaceutical Company Limited
Product Code: SR112025A4505

The global immunoglobulin market size was valued at USD 16.45 Billion in 2024. Looking forward, IMARC Group estimates the market to reach USD 25.77 Billion by 2033, exhibiting a CAGR of 4.70% during 2025-2033. North America currently dominates the market with 46.5% of the share in 2024. The market is primarily driven by the rising incidences of immune disorders, increasing geriatric population, ongoing advancements in immunotherapy treatments, expanding product employment in neurology and hematology, and growing awareness about primary immunodeficiency disorders (PIDD) and other autoimmune diseases.

The main driving factor of the market is the increased prevalence of immunodeficiency disorders, such as primary and secondary immunodeficiencies, raising the demand for immunoglobulin therapies. Moreover, ongoing clinical research, along with innovation in immunoglobulin formulations, such as subcutaneous and intravenous delivery methods, is providing an impetus to market growth. For instance, on October 22, 2024, Otsuka Pharmaceutical released promising interim results for their Phase 3 VISIONARY study regarding sibeprenlimab to treat adult patients with IgAN. The study met the primary endpoint after nine months by showing a clinically significant decrease in 24-hour uPCR compared with placebo, without compromising safety. Apart from this, rising awareness and diagnosis of autoimmune diseases have increased the usage of immunoglobulins as an effective treatment modality.

The market in the United States is experiencing significant growth due to the increasing incidence of rare neurological disorders, such as myasthenia gravis and multifocal motor neuropathy, which has fueled demand for immunoglobulin therapies. Apart from this, the presence of advanced healthcare infrastructure in the United States enabling better access to high-cost treatments, is positioning the country as a significant market for immunoglobulin products. Besides this, the implementation of favorable initiatives and tested approvals in the United States further enables wider access to immunoglobulin treatments, ensuring sustained market growth and innovation in this sector. On June 17, 2024, Grifols announced that its subsidiary, Biotest, secured U.S. FDA approval for Yimmugo, an intravenous immunoglobulin therapy for primary immunodeficiencies. This marks Biotest's first FDA-approved treatment, manufactured at its new "Next Level" facility in Dreieich, Germany. The U.S. launch of Yimmugo(R) in the latter half of 2024 is expected to significantly contribute to Grifols Group's sales and support its future growth strategy.

Immunoglobulin Market Trends:

Increasing prevalence of immune disorders

The rising incidence of immune disorders, such as PIDD, chronic inflammatory demyelinating polyneuropathy (CIDP), and Kawasaki disease, is one of the key trends driving the immunoglobulin market. For instance, the number of new cases per year of CIDP is about 1-2 per 100,000 people. These disorders weaken the body's immune system, making it more susceptible to infections. With a growing number of patients being diagnosed with immune-related conditions, the demand for immunoglobulin therapies is on the rise. PIDD, which comprises over 300 different rare conditions, is gaining increased attention in both developed and emerging economies. Early diagnosis and treatment are critical in managing these conditions, which is further increasing the immunoglobulin demand as the primary treatment option.

Advancements in plasma-derived therapies

Continual advancements in plasma-derived therapies are a significant growth-inducting factor for the market. Primarily, immunoglobulin is derived from human plasma. Technological advancements along the lines of plasma collection and purification further enhance production efficiency. These innovations contribute to a more reliable supply of immunoglobulin products. Additionally, innovations in manufacturing processes improve the quality, safety, and efficacy of these therapies. The development of SCIG products, which allow for self-administration at home, facilitates patient convenience and adherence to treatment. Furthermore, the emergence of recombinant immunoglobulin products, which do not rely on plasma donations, has the potential to alleviate supply constraints while offering an alternative therapeutic option, thereby supporting the immunoglobulin market growth.

Expanding applications in various medical fields

The expanding application of immunoglobulin therapies in various medical fields is providing an impetus to market growth. Beyond its traditional usage in immunology, immunoglobulin is widely employed in neurology, hematology, and even oncology. For instance, the United States spent USD 99 billion on oncology in 2023, up from USD 65 billion in 2019. For example, in neurology, immunoglobulin therapies are increasingly used to treat conditions like Guillain-Barre syndrome, multiple sclerosis, and myasthenia gravis. In hematology, immunoglobulins are used to manage autoimmune hemolytic anemia and idiopathic thrombocytopenic purpura (ITP). These expanding applications are supported by ongoing clinical trials and research efforts exploring the use of immunoglobulins for a wider range of diseases, thus positively impacting the immunoglobulin market outlook.

Immunoglobulin Industry Segmentation:

Analysis by Product:

  • IgG
  • IgA
  • IgM
  • IgE
  • IgD

IgG leads the market with 42.2% of the share in 2024 due to its widespread therapeutic use and central role in the proper functioning of the immune system. As the most abundant antibody circulating in the bloodstream, IgG is indispensable in neutralizing pathogens and mediating immune responses; therefore, it forms an important component in the treatment of primary immunodeficiency diseases, autoimmune diseases, and a variety of infections. Its increasing global prevalence has increased the demand for IgG therapies. Advancements in IgG technology also include enhancement of its purity by extraction, and methods of administration with better efficiency have increased patient safety and acceptance toward it, resulting in adoption.

Analysis by Application:

  • Hypogammaglobulinemia
  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
  • Immunodeficiency Disease
  • Myasthenia Gravis
  • Others

In 2024, immunodeficiency diseases lead the market due to a high and increasingly large prevalence. Immunodeficiency diseases, which comprise primary immunodeficiency diseases, are characterized by a weakened immune system, with patients being very susceptible to infections. Immunoglobulin therapy has become a cornerstone in managing these conditions; it provides patients with essential antibodies that bolster their immune defense. The increase in the incidence of PIDs across the globe, in conjunction with improved diagnostics, raises demand for immunoglobulin products. Increased accessibility due to growth in healthcare infrastructure, as well as entry into specialty treatment centers, expands a patient's access for treatment.

Analysis by Mode of Delivery:

  • Intravenous Mode of Delivery
  • Subcutaneous Mode of Delivery

Intravenous mode of delivery leads the market with 46.5% of the share in 2024. The efficiency and application for treating numerous immune-related conditions provided by intravenous mode of delivery drives its usage in such treatments. Severe and acute conditions like primary immunodeficiency diseases (PIDs), Kawasaki disease, and some neurological disorders require the intravenous delivery of IVIG for its quick bioavailability and therapeutic impact. The growing incidence of these conditions, combined with improvements in the formulation of IVIG, which makes it safer and more convenient for patients, increases demand for this product. Healthcare providers and patients prefer the intravenous route, as it has been well-established to be effective in the treatment of life-threatening complications.

Analysis by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

In 2024, North America leads the immunoglobulin market with 46.5% of the share, due to its advanced health care infrastructure, awareness regarding diseases, and significant expenditure towards research and development (R&D) activities. Its well-built diagnostic capabilities help to recognize the primary condition, that is, immune deficiencies and autoimmune disorders, and therefore create a regular demand for immunoglobulin therapies. Also, an increased older population at higher risk for immune-related disorders results in demand for immunoglobulin. The increasing incidence of primary immunodeficiency diseases, neurological disorders such as Guillain-Barre syndrome, and chronic inflammatory demyelinating polyneuropathy are driving growth in the market. The presence of key biopharmaceutical companies and facilitative regulatory environments make it easier for innovative immunoglobulin products to get through to the market. Positive recompense policies further boost market growth.

Key Regional Takeaways:

United States Immunoglobulin Market Analysis

The US accounted for 83.30% of the overall North America immunoglobulin market share in 2024. Massive growth in the adoption of immunoglobulin treatments is being encouraged in the region due to increasing emphasis on developing advanced healthcare systems. The need for better patient outcomes results in significant investment in healthcare services and biopharmaceutical inventions, which ensures the availability of therapies regarding immune deficiencies. For instance, U.S. healthcare companies are securing venture capital deals of USD 15 Million plus are driving robust investment growth, focusing on innovation in medical technology to meet rising market demands. Expanded access to immunoglobulin products via specialized centers and ongoing improvements in administration techniques streamline the treatment process. Support for rare disease management and comprehensive insurance coverage further supports the adoption of treatments. Improved diagnostics are also instrumental, allowing for earlier detection and more targeted therapeutic interventions. Interdisciplinary collaboration between healthcare providers and research institutes is fueling clinical development and optimizing patient care. Efforts to educate healthcare professionals about the most advanced treatments are empowering the wide usage of immunoglobulin therapies. As funding grows, healthcare systems are better equipped to integrate immunoglobulin into treatment protocols, reinforcing its role in addressing immune-related conditions.

Asia Pacific Immunoglobulin Market Analysis

The rise in immunoglobulin utilization in the region is due to the increase in conditions which require immune system modulation. According to National Library of Medicine, the estimated number of incident cases of cancer in India for the year 2022 was found to be 14,61,427. With more patients diagnosed at advanced stages, the demand for supportive therapies has increased. Expanding medical research focused on adjunctive treatments complements chemotherapy and radiotherapy. Enhanced clinical trial frameworks pave the way for innovations, ensuring tailored solutions for unique patient needs. Hospitals are incorporating cutting-edge biotherapeutic products into treatment guidelines, reflecting a commitment to comprehensive care. Strategic alliances among healthcare providers and educational institutions are fostering awareness regarding immunoglobulin therapies. Upgraded healthcare technologies facilitate the integration of these treatments into routine care. Such advancements, along with patient-centric models, are creating an environment conducive to greater therapeutic adoption. Increased accessibility to specialized medicines is empowering practitioners to incorporate them into a broader spectrum of treatment approaches.

Europe Immunoglobulin Market Analysis

The aging demographic in the region significantly influences the growing application of immunoglobulin therapies. For instance, Europe's ageing population is on the rise, with one in five Europeans now aged 65 or older, projected to approach 30% by 2050. Older adults are more prone to chronic and autoimmune diseases, necessitating comprehensive immune support. Healthcare services are adapting to meet the specific needs of this group, integrating therapies that address immune system vulnerabilities. Regulatory frameworks support the availability of treatments tailored for geriatric care. Continuous advancements in medical education highlight the critical role of immunoglobulin in enhancing life quality among the elderly. Hospitals are expanding immunotherapy units to cater to increased demand, supported by dedicated research programs exploring age-specific applications. The push for seamless patient care experiences includes access to therapies that improve immune function. Elderly-focused healthcare policies emphasize the importance of accessible and effective treatments, driving the systematic inclusion of immunoglobulin in therapeutic regimens.

Latin America Immunoglobulin Market Analysis

Enhanced private healthcare establishments in the region are driving the integration of immunoglobulin therapies. According to International Trade Administration, Brazil is the largest healthcare market in Latin America with 7,191 hospitals, 62% are private. Advanced medical facilities are offering treatments that cater to diverse patient needs. Investments in private sectors are enabling the establishment of state-of-the-art centers equipped with modern therapeutic solutions. Specialized healthcare providers are expanding their service portfolios to include immune-focused therapies. Increased collaboration with global institutions ensures that innovative solutions are implemented swiftly. Educational initiatives are informing professionals about the benefits of advanced treatment modalities, encouraging their inclusion in clinical practice. Such developments ensure that immunoglobulin adoption aligns with the growing expectations of quality care delivery.

Middle East and Africa Immunoglobulin Market Analysis

Upgraded healthcare facilities in the region are propelling immunoglobulin applications across various therapeutic areas. According to Dubai Healthcare City Authority report, Dubai's healthcare sector saw rapid growth, with 4,482 private medical facilities and 55,208 licensed professionals by 2022, projected to expand further by 3-6% in facilities and 10-15% in professionals in 2023. The establishment of well-equipped medical centers is creating opportunities to include cutting-edge treatments in standard care practices. Regional healthcare improvements emphasize addressing immune deficiencies with effective biotherapeutics. Specialized services within advanced facilities are incorporating immunoglobulin-based interventions to address a wide range of health conditions. Growing emphasis on patient-centric care and the alignment of health services with global standards are fostering widespread therapy utilization. Enhanced accessibility to immune-focused treatments is enabling healthcare providers to cater to broader patient demographics efficiently.

Competitive Landscape:

The competitive landscape of the market has key players capturing a significant part of the market share, especially with established networks of plasma collection, advanced manufacturing processes, and strong product portfolios. Intense competition is thus created around product formulations, particularly concerning the development of subcutaneous and IVIG therapies that can advance patient outcomes and convenience. In parallel, continuous efforts are placed on supply chains and increasing capacities to produce goods to meet a growing demand. With these considerations, plasma producers have huge entrance barriers mainly characterized by intricate requirements in the aspect of regulatory laws and rather stringent standards of quality. Companies make considerable mergers and acquisitions for strengthened market position along with strategic partnering. Furthermore, research and development (R&D) for recombinant immunoglobulins, as well as alternate forms of therapies, raise the dynamics of competition within this industry.

The report provides a comprehensive analysis of the competitive landscape in the immunoglobulin market with detailed profiles of all major companies, including:

  • ADMA Biologics Inc.
  • Baxter international Inc.
  • Biotest AG
  • CSL Limited
  • Grifols S.A
  • Kedrion S.p.A
  • LFB SA
  • Octapharma AG
  • Sanquin Plasma Products B.V.
  • Takeda Pharmaceutical Company Limited

Key Questions Answered in This Report

  • 1.What is Immunoglobulin?
  • 2.How big is the immunoglobulin market?
  • 3.What is the expected growth rate of the global Immunoglobulin market during 2025-2033?
  • 4.What are the key factors driving the global Immunoglobulin market?
  • 5.What is the leading segment of the global Immunoglobulin market based on the product?
  • 6.What is the leading segment of the global Immunoglobulin market based on application?
  • 7.What is the leading segment of the global Immunoglobulin market based on the mode of delivery?
  • 8.What are the key regions in the global Immunoglobulin market?
  • 9.Who are the key players/companies in the global Immunoglobulin market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Immunoglobulin Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product

  • 6.1 IgG
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 IgA
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 IgM
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 IgE
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 IgD
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast

7 Market Breakup by Application

  • 7.1 Hypogammaglobulinemia
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Immunodeficiency Disease
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Myasthenia Gravis
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Others
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by Mode of Delivery

  • 8.1 Intravenous Mode of Delivery
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Subcutaneous Mode of Delivery
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 ADMA Biologics Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
    • 14.3.2 Baxter international Inc.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Biotest AG
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 CSL Limited
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 Grifols S.A
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 Kedrion S.p.A
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
    • 14.3.7 LFB SA
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
    • 14.3.8 Octapharma AG
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 SWOT Analysis
    • 14.3.9 Sanquin Plasma Products B.V.
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
    • 14.3.10 Takeda Pharmaceutical Company Limited
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Immunoglobulin Market: Major Drivers and Challenges
  • Figure 2: Global: Immunoglobulin Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Immunoglobulin Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 4: Global: Immunoglobulin Market: Breakup by Product (in %), 2024
  • Figure 5: Global: Immunoglobulin Market: Breakup by Application (in %), 2024
  • Figure 6: Global: Immunoglobulin Market: Breakup by Mode of Delivery (in %), 2024
  • Figure 7: Global: Immunoglobulin Market: Breakup by Region (in %), 2024
  • Figure 8: Global: Immunoglobulin (IgG) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 9: Global: Immunoglobulin (IgG) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 10: Global: Immunoglobulin (IgA) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 11: Global: Immunoglobulin (IgA) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 12: Global: Immunoglobulin (IgM) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 13: Global: Immunoglobulin (IgM) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 14: Global: Immunoglobulin (IgE) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 15: Global: Immunoglobulin (IgE) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 16: Global: Immunoglobulin (IgD) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 17: Global: Immunoglobulin (IgD) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 18: Global: Immunoglobulin (Hypogammaglobulinemia) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 19: Global: Immunoglobulin (Hypogammaglobulinemia) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 20: Global: Immunoglobulin (Chronic Inflammatory Demyelinating Polyneuropathy-CIDP) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 21: Global: Immunoglobulin (Chronic Inflammatory Demyelinating Polyneuropathy-CIDP) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 22: Global: Immunoglobulin (Immunodeficiency Disease) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 23: Global: Immunoglobulin (Immunodeficiency Disease) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 24: Global: Immunoglobulin (Myasthenia Gravis) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 25: Global: Immunoglobulin (Myasthenia Gravis) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 26: Global: Immunoglobulin (Other Applications) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 27: Global: Immunoglobulin (Other Applications) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 28: Global: Immunoglobulin (Intravenous Mode of Delivery) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 29: Global: Immunoglobulin (Intravenous Mode of Delivery) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 30: Global: Immunoglobulin (Subcutaneous Mode of Delivery) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 31: Global: Immunoglobulin (Subcutaneous Mode of Delivery) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 32: North America: Immunoglobulin Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 33: North America: Immunoglobulin Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 34: United States: Immunoglobulin Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 35: United States: Immunoglobulin Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 36: Canada: Immunoglobulin Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 37: Canada: Immunoglobulin Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 38: Asia-Pacific: Immunoglobulin Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 39: Asia-Pacific: Immunoglobulin Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 40: China: Immunoglobulin Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 41: China: Immunoglobulin Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 42: Japan: Immunoglobulin Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 43: Japan: Immunoglobulin Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 44: India: Immunoglobulin Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 45: India: Immunoglobulin Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 46: South Korea: Immunoglobulin Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 47: South Korea: Immunoglobulin Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 48: Australia: Immunoglobulin Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 49: Australia: Immunoglobulin Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 50: Indonesia: Immunoglobulin Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 51: Indonesia: Immunoglobulin Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 52: Others: Immunoglobulin Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 53: Others: Immunoglobulin Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 54: Europe: Immunoglobulin Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 55: Europe: Immunoglobulin Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 56: Germany: Immunoglobulin Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 57: Germany: Immunoglobulin Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 58: France: Immunoglobulin Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 59: France: Immunoglobulin Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 60: United Kingdom: Immunoglobulin Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 61: United Kingdom: Immunoglobulin Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 62: Italy: Immunoglobulin Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 63: Italy: Immunoglobulin Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 64: Spain: Immunoglobulin Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 65: Spain: Immunoglobulin Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 66: Russia: Immunoglobulin Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 67: Russia: Immunoglobulin Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 68: Others: Immunoglobulin Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 69: Others: Immunoglobulin Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 70: Latin America: Immunoglobulin Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 71: Latin America: Immunoglobulin Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 72: Brazil: Immunoglobulin Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 73: Brazil: Immunoglobulin Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 74: Mexico: Immunoglobulin Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 75: Mexico: Immunoglobulin Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 76: Others: Immunoglobulin Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 77: Others: Immunoglobulin Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 78: Middle East and Africa: Immunoglobulin Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 79: Middle East and Africa: Immunoglobulin Market: Breakup by Country (in %), 2024
  • Figure 80: Middle East and Africa: Immunoglobulin Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 81: Global: Immunoglobulin Industry: SWOT Analysis
  • Figure 82: Global: Immunoglobulin Industry: Value Chain Analysis
  • Figure 83: Global: Immunoglobulin Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Immunoglobulin Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Immunoglobulin Market Forecast: Breakup by Product (in Million USD), 2025-2033
  • Table 3: Global: Immunoglobulin Market Forecast: Breakup by Application (in Million USD), 2025-2033
  • Table 4: Global: Immunoglobulin Market Forecast: Breakup by Mode of Delivery (in Million USD), 2025-2033
  • Table 5: Global: Immunoglobulin Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 6: Global: Immunoglobulin Market: Competitive Structure
  • Table 7: Global: Immunoglobulin Market: Key Players